A trial of prednisolone in combination with SPI-62 in participants with polymyalgia rheumatica (PMR)

2023-507721-41-00 Protocol SPI-62-CL-1002 Human pharmacology (Phase I) - Other Ended

Start 11 Mar 2024 · End 3 Dec 2024 · Status Ended · 1 EU/EEA countries · 5 sites · Protocol SPI-62-CL-1002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 14
Countries 1
Sites 5

polymyalgia rheumatica

Key facts

Sponsor
Sparrow Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
11 Mar 2024 → 3 Dec 2024
Decision date (initial)
2024-02-20
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-507721-41-00
WHO UTN
U1111-1296-6448

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

polymyalgia rheumatica

VersionLevelCodeTermSystem organ class
21.0 PT 10036099 Polymyalgia rheumatica 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sparrow Pharmaceuticals Inc.

Sponsor organisation
Sparrow Pharmaceuticals Inc.
Address
920 Southwest 6th Avenue
City
Portland
Postcode
97204-1239
Country
United States

Scientific contact point

Organisation
Sparrow Pharmaceuticals Inc.
Contact name
Scientific contact point

Public contact point

Organisation
Sparrow Pharmaceuticals Inc.
Contact name
Scientific contact point

Locations

1 EU/EEA country · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 14 5
Rest of world 0

Investigational sites

Germany

5 sites · Ended
Klinische Forschung Hannover-Mitte GmbH
n.a., Schillerstrasse 30, Mitte, Hanover
Klinische Forschung Schwerin GmbH
n.a., Friedrichstrasse 1, Altstadt, Schwerin
Emovis GmbH
n.a., Bezirk Charlottenburg Wilmersdorf, Wilmersdorfer Strasse 79, Berlin
Klinikum der Universitaet Muenchen AöR
Medizinische Klinik und Poliklinik IV, Pettenkoferstrasse 8a, Ludwigsvorstadt-Isarvorstadt, Munich
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
I. Medizinische Klinik und Poliklinik: Rheumatologie und klinische Immunologie, Langenbeckstrasse 1, Oberstadt, Mainz

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-03-11 2024-04-02 2024-06-03

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-10-27 Germany Acceptable
2024-02-19
2024-02-20
2 SUBSTANTIAL MODIFICATION SM-1 2024-02-29 Germany Acceptable 2024-04-19